Pharma Breathes Sigh Of Relief Over Post-Brexit Trade Deal
Despite Cautious Welcome, Industry Warns That The Story Is Far From Over
The devil will be in the detail but the UK/EU industry's first reaction to the last-minute post-Brexit trade deal is one of relief.
You may also be interested in...
The trade deal agreed by the EU and the UK may have brought some relief to the life sciences sector in that it averts the chaos that would have followed failure to reach a deal, but it contains little that will have a direct impact on the regulation of medicines.
Excluding the multinational majors AstraZeneca and GSK, the UK has yet to produce a truly successful scaled pharma company, despite having boasted several innovative start-ups. Whether that represents a negative, however, is a matter for debate.
The pipeline to treat the neurological disorder, which is characterized by uncontrolled rapid and repeated movements or sounds, is very thin but a couple of biotechs either side of the Atlantic are making progress.